156 related articles for article (PubMed ID: 29447458)
1. E-Cadherin Loss Accelerates Tumor Progression and Metastasis in a Mouse Model of Lung Adenocarcinoma.
Sinkevicius KW; Bellaria KJ; Barrios J; Pessina P; Gupta M; Brainson CF; Bronson RT; Kim CF
Am J Respir Cell Mol Biol; 2018 Aug; 59(2):237-245. PubMed ID: 29447458
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin Expression.
Till JE; Yoon C; Kim BJ; Roby K; Addai P; Jonokuchi E; Tang LH; Yoon SS; Ryeom S
Cancer Res; 2017 Oct; 77(19):5349-5359. PubMed ID: 28760854
[TBL] [Abstract][Full Text] [Related]
3. KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem-Like Cells and Promotes Metastasis.
Yoon C; Till J; Cho SJ; Chang KK; Lin JX; Huang CM; Ryeom S; Yoon SS
Mol Cancer Res; 2019 Sep; 17(9):1945-1957. PubMed ID: 31217166
[TBL] [Abstract][Full Text] [Related]
4. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.
Stark AP; Chang HH; Jung X; Moro A; Hertzer K; Xu M; Schmidt A; Hines OJ; Eibl G
Surgery; 2015 Dec; 158(6):1564-72. PubMed ID: 26297056
[TBL] [Abstract][Full Text] [Related]
6. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
Kasinski AL; Slack FJ
Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract][Full Text] [Related]
8. Cooperativity of E-cadherin and Smad4 loss to promote diffuse-type gastric adenocarcinoma and metastasis.
Park JW; Jang SH; Park DM; Lim NJ; Deng C; Kim DY; Green JE; Kim HK
Mol Cancer Res; 2014 Aug; 12(8):1088-99. PubMed ID: 24784840
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
10. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
Drosten M; Barbacid M
J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
[TBL] [Abstract][Full Text] [Related]
11. KIF13B-NRG1 Gene Fusion and KRAS Amplification in a Case of Natural Progression of Lung Cancer.
Xia D; Le LP; Iafrate AJ; Lennerz J
Int J Surg Pathol; 2017 May; 25(3):238-240. PubMed ID: 28391773
[TBL] [Abstract][Full Text] [Related]
12. CD44 promotes Kras-dependent lung adenocarcinoma.
Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
[TBL] [Abstract][Full Text] [Related]
13. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
[TBL] [Abstract][Full Text] [Related]
14. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
Baek KH; Bhang D; Zaslavsky A; Wang LC; Vachani A; Kim CF; Albelda SM; Evan GI; Ryeom S
J Clin Invest; 2013 Oct; 123(10):4375-89. PubMed ID: 24018559
[TBL] [Abstract][Full Text] [Related]
15. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
Rachagani S; Senapati S; Chakraborty S; Ponnusamy MP; Kumar S; Smith LM; Jain M; Batra SK
Br J Cancer; 2011 Mar; 104(6):1038-48. PubMed ID: 21364589
[TBL] [Abstract][Full Text] [Related]
16. COL5A1 may contribute the metastasis of lung adenocarcinoma.
Liu W; Wei H; Gao Z; Chen G; Liu Y; Gao X; Bai G; He S; Liu T; Xu W; Yang X; Jiao J; Xiao J
Gene; 2018 Jul; 665():57-66. PubMed ID: 29702185
[TBL] [Abstract][Full Text] [Related]
17. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
[TBL] [Abstract][Full Text] [Related]
18. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.
Gibbons DL; Lin W; Creighton CJ; Zheng S; Berel D; Yang Y; Raso MG; Liu DD; Wistuba II; Lozano G; Kurie JM
PLoS One; 2009; 4(4):e5401. PubMed ID: 19404390
[TBL] [Abstract][Full Text] [Related]
19. More than a Tumor Suppressor: E-Cadherin Loss Drives Lung Cancer Metastasis.
Devlin JR; Verschuren EW
Am J Respir Cell Mol Biol; 2018 Aug; 59(2):141-142. PubMed ID: 29688752
[No Abstract] [Full Text] [Related]
20. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
